PharmEste is a biopharmaceutical company specializing in the discovery and development of therapeutics targeting transient receptor potential (TRP) channels. Their focus is on treating neuropathic pain, overactive bladder, and other TRP-mediated diseases. One of their key developments is PHE377, a TRPV1 antagonist specifically designed for the treatment of neuropathic pain. PharmEste's innovative approach aims to provide effective solutions for patients suffering from these conditions.